255 related articles for article (PubMed ID: 31813996)
1. G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.
Arbez N; He X; Huang Y; Ren M; Liang Y; Nucifora FC; Wang X; Pei Z; Tessarolo L; Smith WW; Ross CA
Hum Mol Genet; 2020 Mar; 29(4):580-590. PubMed ID: 31813996
[TBL] [Abstract][Full Text] [Related]
2. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
[TBL] [Abstract][Full Text] [Related]
7. Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.
Xiong Y; Neifert S; Karuppagounder SS; Liu Q; Stankowski JN; Lee BD; Ko HS; Lee Y; Grima JC; Mao X; Jiang H; Kang SU; Swing DA; Iacovitti L; Tessarollo L; Dawson TM; Dawson VL
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1635-1640. PubMed ID: 29386392
[TBL] [Abstract][Full Text] [Related]
8. Mutant G2019S-LRRK2 Induces Abnormalities in Arteriolar Cerebral Blood Volume in Mouse Brains: An MRI Study.
Ning B; Guo G; Gu C; Xu J; Bibic A; He X; Liu H; Chen L; Wei Z; Duan W; Liu P; Lu H; van Zijl PCM; Ross CA; Smith W; Hua J
Neurodegener Dis; 2020; 20(2-3):65-72. PubMed ID: 33152738
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
[TBL] [Abstract][Full Text] [Related]
10. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
[TBL] [Abstract][Full Text] [Related]
12. A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in
Lin CH; Lin HY; Fang JM; Chen CC
Aging (Albany NY); 2020 Nov; 12(24):25581-25598. PubMed ID: 33231564
[TBL] [Abstract][Full Text] [Related]
13. A Drosophila model for LRRK2-linked parkinsonism.
Liu Z; Wang X; Yu Y; Li X; Wang T; Jiang H; Ren Q; Jiao Y; Sawa A; Moran T; Ross CA; Montell C; Smith WW
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2693-8. PubMed ID: 18258746
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
eNeuro; 2017; 4(2):. PubMed ID: 28321439
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
16. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
[TBL] [Abstract][Full Text] [Related]
17. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
[TBL] [Abstract][Full Text] [Related]
18. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
19. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
[TBL] [Abstract][Full Text] [Related]
20. Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-α Pathway.
Lin CH; Lin HY; Ho EP; Ke YC; Cheng MF; Shiue CY; Wu CH; Liao PH; Hsu AY; Chu LA; Liu YD; Lin YH; Tai YC; Shun CT; Chiu HM; Wu MS
Mov Disord; 2022 Apr; 37(4):745-757. PubMed ID: 34918781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
